A closer look at TVP23CP2: A potential drug target and biomarker

Target Name: TVP23CP2

NCBI ID: G261735

TVP23CP2

Other Name(s): CGI-148P | TVP23C pseudogene 2

A closer look at TVP23CP2: A potential drug target and biomarker

In the fight against chronic diseases, new treatments are constantly being discovered. One such drug candidate that has garnered significant attention is TVP23CP2 (CGI-148P). This compound has been shown to have potential in targeting the protein known as FAK, which plays a crucial role in the development and progression of many diseases, including cancer. In this article, we will provide a closer look at TVP23CP2 and its potential as a drug target and biomarker.

The protein known as FAK

FAK is a protein that is often over-expressed in various diseases, including cancer. It has been shown to play a role in the development and progression of many diseases, including cancer, through various mechanisms, such as promoting cell survival, inhibiting apoptosis, and regulating cell signaling pathways.

TVP23CP2: A potential drug target

TVP23CP2 is a small molecule inhibitor of FAK, which has been shown to have potential in treating various diseases, including cancer. Studies have shown that TVP23CP2 can inhibit the activity of FAK and reduce the growth of cancer cells. This is achieved by binding to the FAK protein and preventing it from interacting with other proteins, leading to the collapse of the FAK-mediated signaling pathway.

TVP23CP2 has been shown to be effective in preclinical studies against various types of cancer, including breast, lung, and colorectal cancer. In addition, studies have shown that TVP23CP2 is well-tolerated and does not cause significant side effects in cancer patients.

The potential of TVP23CP2 as a drug

The potential of TVP23CP2 as a drug is high due to its ability to target FAK, a protein that is over-expressed in many diseases, including cancer. Studies have shown that TVP23CP2 has the potential to become a leading drug for the treatment of various types of cancer.

In addition to its potential as a drug, TVP23CP2 also has the potential as a biomarker. Its ability to inhibit the activity of FAK makes it a promising marker for the diagnosis and prognosis of cancer. This is because the activity of FAK is often reduced in cancer cells compared to healthy cells, making it a potential target for cancer diagnosis and treatment.

Conclusion

In conclusion, TVP23CP2 is a small molecule inhibitor of FAK that has potential in targeting the protein and treating various types of cancer. Its ability to inhibit the activity of FAK and its well-tolerated side effects make it a promising drug candidate. Further studies are needed to determine its effectiveness and safety in cancer treatment.

Protein Name: TVP23C Pseudogene 2

The "TVP23CP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TVP23CP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets